Abstract:Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics, antiglaucoma, antiepileptic or antiobesity drugs, as well as for the management of acute mountain sickness, idiopathic intracranial hypertension and recently, as antitumor theragnostic agents. Other potential applications include the use of CA inhibitors (CAIs) in inflammatory conditions, cerebral ischemia, neuropathic pain, or for Alzheimer's/Parkinson's disease management. CAs from pathogenic bacteria, fungi, protozoans and nematodes started to be considered as drug targets in recent years, with notable advances registered ultimately. CAIs have a complex multipharmacology probably unique to this enzyme, which has been exploited intensely but may lead to other relevant applications in the future, due to the emergence of drug design approaches which afforded highly isoform-selective compounds for most α-CAs known to date. They belong to a multitude of chemical classes (sulfonamides and isosteres, (iso)coumarins and related compounds, mono- and dithiocarbamates, selenols, ninhydrines, boronic acids, benzoxaboroles, etc). The polypharmacology of CAIs will also be discussed since drugs originally discovered for the treatment of non-CA related conditions (topiramate, zonisamide, celecoxib, pazopanib, thiazide and high-ceiling diuretics) show efective inhibition against many CAs, which led to their repurposing for diverse pharmacological applications. Significance Statement Carbonic anhydrase inhibitors have multiple pharmacologic applications as diuretics, antiglaucoma, antiepileptic, antiobesity, anti-acute mountain sickness, anti-idiopathic intracranial hypertension and as antitumor drugs. Their use in inflammatory conditions, cerebral ischemia, neuropathic pain, or neurodegenerations started to be investigated recently. Parasite carbonic anhydrases are also drug targets for antiinfectives with novel mechanisms of action which can by pass drug resistance to commonly used such agents. Drugs discovered for the management of other conditions that effectively inhibit these enzymes exert interesting polypharmacologic effects.

Carbonic anhydrase: its inhibitors and activators

Carbonic anhydrase inhibitors and activators for novel therapeutic applications

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

Carbonic anhydrase activators

Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas

Carbonic anhydrase inhibitors and their therapeutic potential

Carbonic anhydrase inhibitors and activators and their use in therapy

Applications of carbonic anhydrase inhibitors and activators in therapy

Designing of novel carbonic anhydrase inhibitors and activators

Emerging role of carbonic anhydrase inhibitors

Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?

Carbonic anhydrase inhibitors: an editorial

Carbonic anhydrase inhibitors

Drug interactions of carbonic anhydrase inhibitors and activators

Modulation of carbonic anhydrase activity and its applications in therapy

Advances in structure-based drug discovery of carbonic anhydrase inhibitors

Carbonic anhydrases: Moiety appended derivatives, medicinal and pharmacological implications

Multi- and poly-pharmacology of carbonic anhydrase inhibitors

Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO2 capture

Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets

Carbonic anhydrases as drug targets-an overview